Edwards Lifesciences (EW.N), opens new tab missed second-quarter revenue estimates on Wednesday, hurt by lower-than-expected demand for its artificial heart valves.
Shares of the California-based company were down 14.3% at $74.50 after the bell.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,